Today: 7 February 2026
Subscribe
Browse Category

Healthcare Industry News 14 January 2026 - 23 January 2026

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
······
Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

Intuitive Surgical reported Q4 revenue up 19% to $2.87 billion and adjusted earnings of $2.53 per share, beating analyst estimates. Shares rose about 3% in after-hours trading. The company forecast 13% to 15% growth in da Vinci procedures for 2026, slower than 2025, and warned tariffs may pressure margins. Intuitive installed 532 da Vinci systems in the quarter, ending 2025 with 11,106 in use.
22 January 2026
·····
Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott shares fell 7.4% to $111.74 after quarterly revenue missed estimates and the company issued a weaker profit forecast. Fourth-quarter sales dropped to $11.46 billion, below the $11.80 billion expected. Nutrition revenue declined 8.9%, and diagnostics fell 2.5%. The company cited lower volumes and price actions in nutrition and forecast new product launches in 2026.
22 January 2026
·····
Thermo Fisher stock price rises nearly 2% as Australia starts Clario deal review; earnings next in focus

Thermo Fisher stock price rises nearly 2% as Australia starts Clario deal review; earnings next in focus

Thermo Fisher shares rose 1.9% to $630.48 Wednesday after Australia’s ACCC began a Phase 1 review of its planned Clario acquisition, with a decision due by March 2. The company will report fourth-quarter and full-year results on January 29. Investors are watching for updates on 2026 demand and deal timing.
21 January 2026
····
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
·····
Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

Intuitive Surgical shares fell 1.5% to $526.76 Tuesday afternoon, mirroring broader U.S. market declines. The company is set to report earnings Jan. 22 after signaling da Vinci procedure growth of 13%–15% in 2026 and preliminary Q4 revenue near $2.87 billion. Investors remain focused on procedure outlook and competition from Medtronic and Johnson & Johnson.
20 January 2026
·····
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Copenhagen, January 17, 2026, 21:05 CET — The market has closed. Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle. (Investing.com) This move is crucial since investors need clear evidence that Novo’s obesity franchise can sustain growth amid rising competition. Early prescription figures are now seen as indicators of pricing strength, market access, and the pace at which demand expands beyond weekly injections.
17 January 2026
·····
Intuitive Surgical stock slips again as 2026 da Vinci outlook hangs over ISRG ahead of earnings

Intuitive Surgical stock slips again as 2026 da Vinci outlook hangs over ISRG ahead of earnings

New York, Jan 16, 2026, 13:19 EST — Regular session Intuitive Surgical shares slid on Friday, extending a pullback that followed the company’s softer-than-expected outlook for growth in procedures on its flagship da Vinci surgical robots. The stock was down 0.9% at $536.49 in early afternoon trading. The near-term focus is procedure growth — the number of operations done using Intuitive’s systems — because it feeds demand for the company’s instruments and accessories, the higher-frequency part of its business. That matters now because the company’s latest range for 2026 da Vinci procedure growth came in below what some investors had
16 January 2026
·····
Venus Concept stock price jumps nearly 400% as Madryn flags possible delisting in filing

Venus Concept stock price jumps nearly 400% as Madryn flags possible delisting in filing

New York, Jan 16, 2026, 10:39 EST — Regular session Venus Concept Inc. shares surged over 390% on Friday, closing near $7.06 after an early range from $2.27 to $7.75. Trading volume exceeded 155 million shares. Late Thursday, Madryn Asset Management filed an amended Schedule 13D/A revealing it controls 91% of Venus Concept’s outstanding shares. The filing also noted Madryn urged the board to reduce operating costs, possibly by delisting and deregistering the stock. (SEC) This is significant since a 91% owner holds enough sway to push through major corporate moves, like restructurings that might dilute minority shareholders or alter
16 January 2026
·····
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston, Jan 15, 2026, 08:19 (EST) Boston Scientific announced Thursday it will acquire medical device maker Penumbra for roughly $14.5 billion in a cash-and-stock transaction, valuing Penumbra at $374 per share. Penumbra’s shares jumped over 13% in premarket trading. The offer comes at a 19.3% premium to Penumbra’s previous close, Reuters reported. (Reuters) The deal is significant as it drives Boston Scientific further into a vascular medicine segment that’s attracting investment and competition. With procedure volumes climbing and hospitals favoring less invasive treatments, device makers are betting heavily on cardiovascular growth. Penumbra’s main focus is thrombectomy, a catheter-based method for
15 January 2026
····
Smith & Nephew stock drops in London as investors size up $450m Integrity Orthopaedics deal

Smith & Nephew stock drops in London as investors size up $450m Integrity Orthopaedics deal

London, Jan 14, 2026, 09:34 GMT — Regular session underway Smith & Nephew (SN.L) slipped 2.6% to 1,172 pence by 0915 GMT, lagging behind an already soft UK health care equipment and services sector. (sharecast.com) The shares fell just two days after British medical products firm Smith & Nephew announced its plan to acquire U.S.-based Integrity Orthopaedics for as much as $450 million. The company said it would pay $225 million in cash upfront, with an additional $225 million contingent on performance milestones over five years. Smith & Nephew expects the deal to boost its trading profit margin — its
14 January 2026
···
1 2 3 4 5 6 … 12

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop